Furthermore, in the present study, ERK1/2 signaling was found to be enriched in NM patients after intrathecal chemotherapy and systemic therapy, indicating that the change in the ERK1/2 signaling could be associated with treatment resistance. The gene discussed is MAPK3; the disease is nemaline myopathy.